SCHEMBL574810

SCHEMBL574810

CCCCCCCCCc1ccccc1C=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.58
THRB P10828 2/20 0.48
THRA P10827 1/20 0.48
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
BID P55957 3/20 0.45
MCL1 Q07820 3/20 0.45
BCL2L1 Q07817 2/20 0.45
BAK1 Q16611 2/20 0.45
KAT8 Q9H7Z6 2/20 0.45
SAE1 Q9UBE0 2/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
EP300 Q09472 1/20 0.45
KAT2A Q92830 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT5 Q92993 1/20 0.45
HIF1A Q16665 1/20 0.45
EPAS1 Q99814 1/20 0.45
CYSLTR2 Q9NS75 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970921 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL9859793 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL27261574 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL10716860 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL6679819 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL5171915 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL28410253 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL9479874 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL20594223 1.00 LIPG (0.58) LIPGTHRBTHRANR1H2NR1H3
SCHEMBL617128 0.98 LIPG (0.55) LIPGTHRBTHRANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595936-B1 COMPOSITION FOR EXTERNAL USE VITAMIN C60 BIORES CORP (JP) 2011-10-19 EP claimed
US-20060134095-A1 Antioxidative composition and composition for external use VITAMIN C60 BIORESEARCH CORPORATION (JP) 2006-06-22 US claimed
EP-1595936-A1 ANTIOXIDATIVE COMPOSITION AND COMPOSITION FOR EXTERNAL USE MITSUBISHI CORPORATION (JP) 2005-11-16 EP claimed
EP-4682106-A1 FATTY ACID-TREATED ZINC OXIDE PARTICLES, METHOD FOR PRODUCING SAME, AND DISPERSION AND COSMETIC HAVING SAME BLENDED THEREIN Sakai Chemical Industry Co., Ltd. (JP) 2026-01-21 EP disclosed
EP-4620453-A1 AQUEOUS DISPERSION OF SURFACE-HYDROPHOBIZED INORGANIC POWDER AND COSMETIC PREPARATION CONTAINING SAME Nikko Chemicals Co., Ltd. (JP) 2025-09-24 EP disclosed
WO-2025105415-A1 MELANOGENESIS INHIBITOR AND EXTERNAL PREPARATION FOR SKIN CONTAINING SAME 三菱瓦斯化学株式会社 2025-05-22 WO disclosed
CN-119497608-A Composition and method for producing the same 株式会社资生堂 2025-02-21 CN disclosed
US-20250034401-A1 ZINC OXIDE PARTICLES EACH HAVING SURFACE COATED WITH ORGANOSILICON, METHOD FOR PRODUCING SAME, COSMETIC PREPARATION, DISPERSION, HEAT DISSIPATING FILLER AND RESIN COMPOSITION SAKAI CHEMICAL INDUSTRY CO., LTD. (JP) 2025-01-30 US disclosed
US-12109294-B2 Oily moisturizer and topical skin composition containing same THE NISSHIN OILLIO GROUP, LTD. (JP) 2024-10-08 US disclosed
WO-2024204123-A1 FATTY ACID-TREATED ZINC OXIDE PARTICLES, METHOD FOR PRODUCING SAME, AND DISPERSION AND COSMETIC HAVING SAME BLENDED THEREIN 堺化学工業株式会社 2024-10-03 WO disclosed
EP-4424641-A1 ZINC OXIDE PARTICLES EACH HAVING SURFACE COATED WITH ORGANOSILICON, METHOD FOR PRODUCING SAME, COSMETIC PREPARATION, DISPERSION, HEAT DISSIPATING FILLER AND RESIN COMPOSITION Sakai Chemical Industry Co., Ltd. (JP) 2024-09-04 EP disclosed
EP-0225602-B1 ALPHA-HYDROXYTHIO ETHERS CIBA-GEIGY AG (CH) 1991-10-09 EP disclosed
EP-0228045-B1 AROMATIC THIOETHERS CIBA-GEIGY AG (CH) 1991-04-03 EP disclosed
US-4919846-A Conditioning low skin sensitivity SHISEIDO COMPANY LTD. (JP) 1990-04-24 US disclosed
EP-0348091-A1 Aerosol composition SHISEIDO COMPANY LIMITED (JP) 1989-12-27 EP disclosed
US-4808572-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1989-02-28 US disclosed
EP-0303713-A1 PERCUTANEOUS ABSORPTION PROMOTER AND DERMATOLOGIC PREPARATION FOR EXTERNAL USE SHISEIDO COMPANY LIMITED (JP) 1989-02-22 EP disclosed
US-4785004-A ANTIALLERGENS, ANTIHISTAMINES CIBA-GEIGY CORPORATION (US) 1988-11-15 US disclosed
EP-0228045-A2 Aromatic thioethers CIBA-GEIGY AG (CH) 1987-07-08 EP disclosed
EP-0225602-A2 Alpha-hydroxythio ethers CIBA-GEIGY AG (CH) 1987-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060134095-A1 Antioxidative composition and composition for external use GPX4, GPX1, SOD1 LIPG 725/4885THRB 4553/4885THRA 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.